2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1802

Prevalence of CMV in the Ohio State University Lupus Population

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1800

Prevalence of ECG Cardiovascular Abnormalities in Lupus Patients: A Novel Approach Using 5 ECG Elements

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1743

Prevalence of Inflammatory Neck Pain in a Cohort of Patients with Psoriatic Arthritis and Its Association with Clinical and Radiographic Features

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - ARHP Poster

9:00AM-11:00AM: Abstract Number: 1176

Prevalence of Influenza and Pneumococcal Polysaccharide Vaccine Administration and the Factors Affecting Vaccine Uptake in a Population of Patients with Autoimmune Inflammatory Rheumatic Diseases in a Brooklyn Clinic

Epidemiology and Public Health - Poster II

9:00AM-11:00AM: Abstract Number: 1807

Prevalence of Progressive Multifocal Leukoencephalopathy in Adults and Children with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1585

Previous Use of Conventional Disease-Modifying Antirheumatic Drugs and Response to Baricitinib

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1318

Profile of Macrophage-Derived Cytokines and Chemokines of Patients with Chikungunya-Induced Chronic Arthralgia/Arthritis

Infection-related Rheumatic Disease - Poster

9:00AM-11:00AM: Abstract Number: 1717

Progression of Radiographic Axial Damage in Patients with Psoriatic Arthritis. Relation with Clinical and Analytical Factors

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1497

Progressive Decline of Lung Function in Rheumatoid Arthritis Associated Interstitial Lung Disease

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1184

Projected 2015 Prevalence of Physician-Diagnosed Primary SjöGren’s Syndrome Based on 1976-2005 Annual Incidence Rates in a Well-Defined U.S. Population

Epidemiology and Public Health - Poster II

9:00AM-11:00AM: Abstract Number: 1154

Promoting Self-Management Techniques for Osteoarthritis Pain: a Pilot Study of Nurse Practitioner Led Coping Skills Training

Education - ARHP Poster

9:00AM-11:00AM: Abstract Number: 1108

Protein Citrullinations By PAD Enzymes Promote Dendritic Cell Transdifferentiation into Osteoclast and Generate Targets for RA-Specific Antibodies

Biology and Pathology of Bone and Joint - Poster II

9:00AM-11:00AM: Abstract Number: 1664

Protein Fingerprinting Screening Specific Proteins in Serum of Patients with Ankylosing Spondylitis

Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster I

9:00AM-11:00AM: Abstract Number: 1804

Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: a Single Centre Experience

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1780

Pulmonary Disease in Late Versus Early Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].